US Medical Early Asset Director– Insights

US Medical Early Asset Director– Insights  

Are you ready to turn ideas into life-changing medicines? At AstraZeneca, we are committed to addressing the unmet needs of patients worldwide through scientific innovation. In this role, you will play a crucial role in leveraging our scientific capabilities to positively impact patients' lives. Reporting directly to the Executive Director, US Medical Early Asset Team Lead, you will be part of a team focused on the development of ambitious US medical strategies for our early pipeline. This is an opportunity to seize, design, and influence across a complex matrix system to ensure US needs are integrated into global development plans. 

Accountabilities: 
Manager, US Medical Early Asset – Insights will own US insight generation and decision analytics for pipeline assets from late discovery through Phase 2. You will translate ambiguity into clear, evidence-based recommendations by integrating secondary analytics, custom market research, competitive intelligence, epidemiology, and early forecasting. Partnering closely with Global/US Commercial, Medical, Clinical Development, Market Access, HEOR, and Finance, you will shape target product profiles, influence trial design, pressure-test differentiation hypotheses, and inform investment decisions at stage gates. 

Key Responsibilities 

• Insight Strategy and Roadmap: Define the US insights learning plan across asset stages; prioritize critical unknowns and decision points, and map research/analytics to governance milestones. 

• Target Product Profile and Asset Shaping: Pressure-test TPP elements (endpoints, attributes, device/format, administration setting, line of therapy, subsegments) via research and rapid experiments; recommend trade-offs to maximize US value. 

• Primary Market Research: Design and lead payer/HCP/patient qualitative and quantitative studies (concept tests, message/value testing, conjoint/DTU, ethnography, discrete choice, max-diff) to refine positioning and evidence needs. 

• Secondary Analytics: Synthesize syndicated data, claims/EMR analyses, epidemiology, treatment paradigms, and policy trends to size opportunities, refine segmentation, and anticipate adoption barriers. 

• Competitive Intelligence: Maintain dynamic competitor profiles, trial readouts, label trajectories, and access precedents; run competitor simulations and implications for differentiation and timing. 

• Early Forecasting and Scenarios: Build and refine early demand/adoption forecasts, market maps, and scenario trees; partner with Finance on rNPV and sensitivity analyses that reflect uncertainty and key inflection points. 

• Evidence and Trial Design Input: Translate insight into guidance on endpoints, comparators, PROs, inclusion/exclusion, and RWE priorities that support future US adoption, labeling, and access. 

• Customer and Ecosystem Mapping: Identify priority segments (HCPs, treatment centers, IDNs, payers, patient pathways) and define decision drivers across the care continuum to inform early brand strategy and initial field teams' structure. 

• Value Proposition Development: Co-create early value narratives and differentiation hypotheses; test resonance and credibility with customers and iterate with Medical/HEOR and Market Access. 

• Rapid Test-and-Learn: Stand up lightweight experiments (concept sprints, ad boards, rapid quant) t